Revefenacin: Difference between revisions

Jump to navigation Jump to search
Line 33: Line 33:


==Pharmacology==
==Pharmacology==
See Clinical Trials


==Clinical Studies==
==Clinical Studies==

Revision as of 03:52, 8 October 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Uma Maveli[2]

Overview

Adult Indications and Dosage

  • The agreed dosage is 175 micrograms per day
    • Taken via a standard jet nebulizer (turns liquid medication into mist) connected to an air compressor
    • Makes it easy for patients with pulmonary problems

Pediatric Indications and Dosage

Contradictions

Warnings

Adverse Reactions

Side Effects

  • Headache
  • Cough
  • Problems regarding the upper respiratory system
  • Back Pain

Drug Interactions

Use in Specific Populations

IV Compatibility

  • Intravenous solution in healthy volunteers
    • Volume of distribution was 218 L
    • Intravenous solution radioactivity:
    • 54% came out as solid waste
    • 27% came out as liquid waste

Pharmacology

See Clinical Trials

Clinical Studies

Trials:

  • Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD
  • 88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better)

How is it supplied

  • Given to patients via jet nebulizer

Patient Counseling Information

Precautions with Alcohol

Brand Names

  • Yupelri